Docetaxel

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of the CHAARTED 2 cooperative group studies into metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.

CHICAGO — Individuals with KRAS-mutant lung cancer treated with adagrasib experienced significantly prolonged PFS compared with docetaxel, randomized study results presented at ASCO Annual Meeting showed.

Healio spoke with Hossein Borghaei, DO, MS, about results from the SAPPHIRE trial presented at this year’s ESMO Congress.

Several practice-changing clinical trials in recent years have led to the understanding that combination treatments are most effective for patients with advanced prostate cancer.

Datopotamab deruxtecan improved PFS compared with standard chemotherapy for patients with advanced non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

The addition of sitravatinib to nivolumab failed to extend OS, when compared with docetaxel, among certain patients with nonsquamous non-small cell lung cancer, according to topline data from the agent’s manufacturer.

In this video, Shilpa Gupta, MD, Director of Genitourinary Medical Oncology at Taussig Cancer Institute, discusses data from the TRITON3 trial presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Rucaparib significantly improved radiographic PFS compared with physician’s choice of therapy for men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.

The addition of tumor treating fields to standard therapies significantly improved OS for certain patients with non-small cell lung cancer, according to the therapy’s manufacturer.